Skip to content

Daniel E. Roberts

8 papers in the library · 65 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

A Multi-Site Evaluation of a Psychedelic Medicine Curriculum for Psychiatry Trainees.

Academic Psychiatry September 23, 2026 Mary E. Yaden, Kelley C O'Donnell, Daniel E. Roberts et al.

Interest in psychedelic medicine is increasing, yet psychiatry trainees report limited education in this area. The authors developed a standardized curriculum and evaluated its impact on trainee knowledge and attitudes toward psychedelic medicines. A 6-h psychedelic medicine course was delivered across four psychiatry residency programs in the Northeast United States in 2025-2026. The...

DOI: 10.1007/s40596-026-02444-3 (opens in new tab) Full text (opens in new tab) Curriculum Graduate medical education Psychedelic medicine Psychiatry residents

Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial

PsyArXiv March 26, 2026 Broc A. Pagni, Stephen Ross, Sarah E. Mennenga et al. preprint

Background: Psilocybin-assisted therapy (PAT) has shown promise for alcohol use disorder (AUD) in randomized controlled trials (RCTs). However, the effects of open-label administration following blinded treatment are unclear. Here, we present safety and efficacy data from an open-label extension of a Phase II RCT (NCT02061293) examining PAT for AUD. Methods: Adults with AUD (N = 59) received a...

Exploring serotonergic psychedelics as a treatment for personality disorders.

Neuropharmacology July 1, 2025 Brennan M. Carrithers, Daniel E. Roberts, Brandon M Weiss et al. 4 citations

Both psychotherapeutic interventions and pharmacological agents have demonstrated limited efficacy in the treatment of personality disorders (PDs). Emerging evidence suggests that psychedelic therapy, already showing promise in treating various psychiatric conditions commonly comorbid with PDs, may exert therapeutic effects by promoting adaptive changes in personality. Thus, psychedelic therapy...

DOI: 10.1016/j.neuropharm.2025.110413 (opens in new tab) Full text (opens in new tab) Psychedelic drugs Character disorders Magic mushroom therapy Personality disorders +6

Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use

Journal of Psychoactive Drugs February 7, 2025 Amy Lehrner, Heather Jackson, David S. Mathai et al. 11 citations

The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for mental health. Despite increasing attention to challenging psychedelic experiences, few studies have explored the relevance of shame-related processes with psychedelic use. This prospective, longitudinal study involved sequential, automated, web-based surveys that...

DOI: 10.1080/02791072.2025.2461997 (opens in new tab) Psilocybin Shame Hallucinogen Clinical psychology

The Effect of Psychedelics on Individuals with a Personality Disorder: Results from two Prospective Cohort Studies

Research Square October 15, 2024 Alexandra R. Gordon, Brennan M. Carrithers, Broc A. Pagni et al. 3 citations preprint

Abstract Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a possible PD treatment, given preliminary evidence for their potential long-term positive effects on psychological functioning. However, little is known about safety or potential therapeutic...

Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.

International Review of Psychiatry September 11, 2024 Mary E. Yaden, Terence H. W. Ching, Noam Goldway et al. 2 citations

OBJECTIVE: The growth of psychedelic medicine creates new challenges in psychiatric education as physicians may soon be responsible for prescribing a number of psychedelic interventions. Despite this growing need for educated providers, very little is known about the training psychiatry residents receive in psychedelic medicine. We conducted a survey to determine the current educational...

DOI: 10.1080/09540261.2024.2397039 (opens in new tab) Psychedelic-assisted therapy Psychedelic therapies Innovative treatments Promising new modalities +11

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Scientific Reports August 22, 2023 Hannes Kettner, Stephen Ross, Richard J. Zeifman et al. 31 citations

Abstract Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health care providers and patients. Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin/LSD anecdotally reduces challenging...

MDMA-Assisted Psychotherapy for Borderline Personality Disorder.

FOCUS: The Journal of Lifelong Learning in Psychiatry October 1, 2022 Jenna M Traynor, Daniel E. Roberts, Stephen Ross et al. 14 citations

Borderline personality disorder is a complex psychiatric disorder with limited treatment options that are associated with large heterogeneity in treatment response and high rates of dropout. New or complementary treatments for borderline personality disorder are needed that may be able to bolster treatment outcomes. In this review, the authors comment on the plausibility for research on...

DOI: 10.1176/appi.focus.20220056 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted psychotherapy Borderline personality disorder Drug treatment/psychopharmacology MDMA-Assisted Psychotherapy +4